Boston Scientific and Angiotech Pharmaceuticals Receive Canadian American Business Council 2005 Achievement Award
08 November 2005 - 9:00PM
PR Newswire (US)
NATICK, Mass. and VANCOUVER, B.C., Nov. 8 /PRNewswire-FirstCall/ --
Boston Scientific Corporation (NYSE:BSX) and Angiotech
Pharmaceuticals, Inc. (Nasdaq: ANPI; TSX: ANP) announced today that
they have jointly received the Canadian American Business Council
(CABC) 2005 Achievement Award, which recognizes innovative and
successful alliances between Canadian and American firms. The award
was presented today at the Council's 11th annual business
achievement awards ceremony and policy forum held in Calgary,
Alberta, Canada. The CABC Achievement Award is given each year to
two companies whose cross-border joint enterprise has demonstrated
strong business growth, remarkable innovation, and the capacity to
provide the allies with a global advantage. The winners are chosen
by an international panel of judges using standards that examine
sustained profitability, job creation, financial strength,
environmental responsibility, corporate synergy, exceptional
imagination and remarkable innovation. "We are very pleased that
our alliance with Angiotech has been recognized by the CABC," said
Jim Tobin, President and Chief Executive Officer of Boston
Scientific. "The innovative combination of our TAXUS(R) stent
technology with Angiotech's paclitaxel drug technology has resulted
in the world's most successful drug-eluting coronary stent system.
The 1.8 million stents implanted to date in patients worldwide is a
testament to the strength of the alliance, and to the employees at
Boston Scientific and Angiotech who made this revolutionary
technology possible." "This award is a tribute to the hard work and
dedication of employees at both companies," said William Hunter,
Chief Executive Officer of Angiotech. "The complexity of the joint
project was enormous but we were able to marry our separate
pharmaceutical and device technologies to deliver an innovative
combination product for the global market." Executives from Boston
Scientific and Angiotech also participated in a policy forum and
panel discussion titled "The Cross Border Security and Prosperity
Partnership". About The Canadian American Business Council The
Canadian American Business Council is the premier voice of the
Canadian-American business community and is headquartered in
Washington, D.C. Established in 1987, the Council is a non-profit,
issues-oriented organization dedicated to elevating the private
sector perspective on issues that affect Canada and the United
States. For more information, please visit
http://www.canambusco.org/. About Angiotech Pharmaceuticals
Vancouver-based Angiotech Pharmaceuticals, Inc., a specialty
pharmaceutical company focusing on drug-coated medical devices and
biomaterials, is dedicated to enhancing the performance of medical
devices and biomaterials through the innovative uses of
pharma-therapeutics. To find out more about Angiotech
Pharmaceuticals, Inc. (Nasdaq: ANPI; TSX: ANP), please visit our
website at http://www.angiotech.com/. About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad
range of interventional medical specialties. For more information,
please visit: http://www.bostonscientific.com/. This press release
contains forward-looking statements. Boston Scientific wishes to
caution the reader of this press release that actual results may
differ from those discussed in the forward-looking statements and
may be adversely affected by, among other things, risks associated
with new product development and commercialization, clinical
trials, intellectual property, regulatory approvals, competitive
offerings, Boston Scientific's overall business strategy, and other
factors described in Boston Scientific's filings with the
Securities and Exchange Commission. CONTACT: Boston Scientific
Angiotech Pharmaceuticals Milan Kofol Todd Young 508-650-8569
604-221-7676 ext 6933 Investor Relations VP Investor Relations
& Communications Boston Scientific Corporation Angiotech
Pharmaceuticals, Inc. Paul Donovan Rui Avelar 508-650-8541
604-221-7676 ext 6996 Media Relations Sr. VP Medical Affairs &
Communications Boston Scientific Corporation Angiotech
Pharmaceuticals, Inc. Wendy Carhart 503-443-7354 Media Relations
Waggener Edstrom Bioscience DATASOURCE: Boston Scientific
Corporation CONTACT: Milan Kofol, Investor Relations,
+1-508-650-8569, Paul Donovan, Media Relations, +1-508-650-8541,
both of Boston Scientific; or Todd Young, VP Investor Relations
& Communications, +1-604-221-7676, ext. 6933, or Rui Avelar,
Sr. VP Medical Affairs & Communications, +1-604-221-7676, ext.
6996, both of Angiotech Pharmaceuticals, Inc.; or Wendy Carhart,
Media Relations of Waggener Edstrom Bioscience, +1-503-443-7354 Web
site: http://www.bostonscientific.com/ http://www.angiotech.com/
http://www.canambusco.org/
Copyright